Scioto Biosciences and Abigail Wexner Research Institute at Nationwide Children’s Hospital Receive a $2.3 Million Phase II SBIR Grant
Scioto Biosciences, a preclinical stage company developing innovative therapies to transform the delivery of microbiome therapeutics, today announced that they are a recipient of a Phase II SBIR grant from the National Institutes of Health (NIH) for $2.3 million.